Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 January 2015Website:
http://www.pieris.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 65 min agoDividend
Analysts recommendations
Institutional Ownership
PIRS Latest News
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Pieris' (PIRS) shares nosedive as its partner decides to discontinue a phase IIa study evaluating elarekibep for treating asthma, based on non-clinical safety data from a toxicology study.
Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate.
Pieris Pharmaceuticals (PIRS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Stephen Yoder - President and Chief Executive Officer Mary Fitzgerald - Vice President, Project Leader Elarekibep Conference Call Participants Roger Song - Jefferies Jonathan Miller - Evercore ISI Rob Andrew - William Blair & Company Operator Hello and welcome to the Pieris Pharmaceuticals, Inc. Year-End 2022 Conference Call and Webcast. [Operator Instructions].
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 15.38% and 10.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What type of business is Pieris Pharmaceuticals?
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
What sector is Pieris Pharmaceuticals in?
Pieris Pharmaceuticals is in the Healthcare sector
What industry is Pieris Pharmaceuticals in?
Pieris Pharmaceuticals is in the Biotechnology industry
What country is Pieris Pharmaceuticals from?
Pieris Pharmaceuticals is headquartered in United States
When did Pieris Pharmaceuticals go public?
Pieris Pharmaceuticals initial public offering (IPO) was on 02 January 2015
What is Pieris Pharmaceuticals website?
https://www.pieris.com
Is Pieris Pharmaceuticals in the S&P 500?
No, Pieris Pharmaceuticals is not included in the S&P 500 index
Is Pieris Pharmaceuticals in the NASDAQ 100?
No, Pieris Pharmaceuticals is not included in the NASDAQ 100 index
Is Pieris Pharmaceuticals in the Dow Jones?
No, Pieris Pharmaceuticals is not included in the Dow Jones index
When does Pieris Pharmaceuticals report earnings?
The next expected earnings date for Pieris Pharmaceuticals is 09 August 2024